Skip to main content

Table 2 Treatment strategies

From: Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

  Pulmonary
embolism
Deep vein
thrombosis
Odds ratio
(95% CI) /
P value
Patients, N 14 9  
Duration of therapy,
  Mean days (SD) 260 ± 254 243 ± 195 P = 0.867
  Median days (IQR) 171 (111–335) 177 (86–475) P = 0.999
Initial therapy,
  Unfractionated heparin 2 (14%) 0
  Low-molecular-weight heparin 10 (71%) 9 (100%)
  Mean LMWH dose (IU/kg/day) 132 ± 50 151 ± 59 P = 0.474
  LMWH doses < 100 IU/kg/day 4 (29%) 2 (22%) 2.33 (0.31–17.55)
  Rivaroxaban 1 (7%) 0
  Inferior vena cava filter (without anticoagulant therapy) 1 (7%) 0
Long-term therapy, 13 9  
  Low-molecular-weight heparin 7 (54%) 6 (67%) 0.58 (0. 10-3.40)
   Mean LMWH dose (IU/kg/day) 135 ± 35 119 ± 43 P = 0.491
   LMWH < 100 IU/kg/day 1 (8%) 2 (22%) 0.27 (0.02–3.52)
  Vitamin K antagonists 5 (38%) 3 (33%) 1.25 (0. 21-7.41)
  Rivaroxaban 1 (8%) 0
  No anticoagulant drugs 0 0
  1. Abbreviations: SD standard deviation, IQR interquartile range, LMWH low-molecular-weight heparin, IU international units, 95%CI, 95% confidence intervals